PubRank

William N Hait

Author PubWeight™ 33.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010 2.06
2 Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res 2006 1.89
3 Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003 1.71
4 The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005 1.57
5 Is anticancer drug development heading in the right direction? Cancer Res 2009 1.56
6 Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002 1.56
7 Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res 2009 1.42
8 Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to Anoikis through inhibition of Bim. J Biol Chem 2006 1.41
9 Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003 1.39
10 Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res 2003 1.33
11 Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007 1.29
12 Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One 2010 1.29
13 Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev 2013 1.25
14 Regulation of the stability of P-glycoprotein by ubiquitination. Mol Pharmacol 2004 1.19
15 Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells. Biochem Pharmacol 2007 1.14
16 Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007 1.10
17 Translating research into clinical practice: deliberations from the American Association for Cancer Research. Clin Cancer Res 2005 1.03
18 Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res 2005 1.01
19 Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma. Clin Cancer Res 2003 0.95
20 A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4. Clin Cancer Res 2002 0.84
21 AACR Cancer Progress Report 2012. Clin Cancer Res 2012 0.82
22 A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells. Cancer Biol Ther 2009 0.82
23 P-glycoprotein mediates resistance to histidine kinase inhibitors. Mol Pharmacol 2004 0.81
24 Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res 2003 0.80
25 Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J Exp Ther Oncol 2002 0.79
26 Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. Breast J 2003 0.78
27 Sustaining the clinical in clinical translational research. Clin Cancer Res 2006 0.78
28 Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol 2002 0.77
29 Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions. Biochem Biophys Res Commun 2012 0.75
30 Updated methods for reporting clinical trials. Clin Cancer Res 2005 0.75